ABCB1 and neoplasm: As the selective pressure of chemotherapy will drive the clonal evolutionary development of both drug-sensitive and drug-resistant populations within the same tumor, we next examined whether agents identified from our primary screen were equally cytotoxic for pure ABCB1 fusion-negative (Clone D) and mixed-fusion (Clone D and Clone 9, 50:50 mix) populations.